Since Venetoclax is targeting the anti-apoptotic BCL-2 protein, we next checked BCL-2 mRNA expression levels in AML and overlaid the CD14+ Monocyte percentages for these cases (Fig. 3d). The gene discussed is BCL2; the disease is acute myeloid leukemia.